Inhibition
Showing 1 - 25 of >10,000
Neck Pain Trial in Lahore (autogenic inhibition, reciprocal inhibition)
Recruiting
- Neck Pain
- autogenic inhibition
- reciprocal inhibition
-
Lahore, Punjab, PakistanNusrat Rashid Medical Complex
Oct 11, 2023
Schizophrenia Trial (repetitive transcranial magnetic stimulation)
Not yet recruiting
- Schizophrenia
- repetitive transcranial magnetic stimulation
- (no location specified)
Nov 22, 2023
Chronic Non Specific Low Back Pain Trial (Experimental: Group A: integrated neuromuscular inhibition technique, Experimental:
Not yet recruiting
- Chronic Non Specific Low Back Pain
- Experimental: Group A: integrated neuromuscular inhibition technique
- +2 more
- (no location specified)
Oct 30, 2023
Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body
Recruiting
- Sarcoma
- +2 more
- Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University, School of Medici
Oct 3, 2023
HFI Trial in Maastricht (PF-06801591)
Recruiting
- HFI
-
Maastricht, Limburg, NetherlandsMaastricht University Medical centre
Oct 16, 2023
Myofascial Trigger Point Pain Trial in Lahore (Integrated Neuromuscular Inhibition Technique, Myofascial Release)
Enrolling by invitation
- Myofascial Trigger Point Pain
- Integrated Neuromuscular Inhibition Technique
- Myofascial Release
-
Lahore, Punjab, PakistanChaudhary Muhammad Akram Hospital
Apr 3, 2023
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure Trial
Not yet recruiting
- Heart Failure NYHA Class II
- +2 more
- (no location specified)
May 22, 2023
Lactation Suppressed, Second Trimester Abortion Trial in Chicago (Cabergoline, Placebo)
Not yet recruiting
- Lactation Suppressed
- Second Trimester Abortion
- Cabergoline
- Placebo
-
Chicago, IllinoisNorthwestern Medical Center
Nov 7, 2023
Depressive Disorder, Major, Inflammation Trial (Infliximab, Placebo)
Not yet recruiting
- Depressive Disorder, Major
- Inflammation
- Infliximab
- Placebo
- (no location specified)
Nov 21, 2023
Kohlmeier Degos Disease With Neurologic Involvement Trial run by the National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
- Kohlmeier Degos Disease With Neurologic Involvement
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 23, 2023
Shoulder Pain Trial (inhibition technique, )
Not yet recruiting
- Shoulder Pain
- inhibition technique
- placebo
- (no location specified)
Jul 15, 2023
Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma Trial in Leiden (Encorafenib + Binimetinib)
Recruiting
- Melanoma Stage III
- In-Transit Metastasis of Cutaneous Melanoma
- Encorafenib + Binimetinib
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Mar 2, 2023
Abdominal Aortic Aneurysm Trial (Evolocumab, Placebo)
Not yet recruiting
- Abdominal Aortic Aneurysm
- Evolocumab
- Placebo
- (no location specified)
Oct 12, 2023
SGLT2 Inhibition in Heart Failure
Recruiting
- Heart Failure
- Sodium-glucose cotransporter 2 inhibitor
-
Belfast, United KingdomBelfast Health and Social Care Trust
Nov 15, 2023
Spinal Cord Injuries Trial in Istanbul (Tendon tap, Tibial nerve stimulation)
Completed
- Spinal Cord Injuries
- Tendon tap
- Tibial nerve stimulation
-
Istanbul, Turkeyİstanbul Physical Therapy Training and Research Hospital
Aug 11, 2023
Aging Trial in Orlando (Abdominal subcutaneous adipose tissue biopsy)
Active, not recruiting
- Aging
- Abdominal subcutaneous adipose tissue biopsy
-
Orlando, FloridaAdventHealth Translational Research Institute
Aug 16, 2023
Type 2 Diabetes, Hypertension Trial in New Orleans (Dapagliflozin, Sulfonylurea, Placebo)
Completed
- Type 2 Diabetes
- Hypertension
- Dapagliflozin
- Placebo
-
New Orleans, LouisianaTulane University
Oct 5, 2022
Anti-cancer Immune Checkpoint Inhibition TowardsBetter
Not yet recruiting
- Cancer
- (no location specified)
Aug 1, 2023
Obesity, Metabolic Syndrome Trial in Nashville (Empagliflozin 25 MG, Placebo)
Not yet recruiting
- Obesity
- Metabolic Syndrome
- Empagliflozin 25 MG
- Placebo
-
Nashville, TennesseeVanderbilt University Medical Center
Jul 24, 2023
Lactation Suppressed Trial in Stanford (Cabergoline 1 MG, Placebo)
Not yet recruiting
- Lactation Suppressed
- Cabergoline 1 MG
- Placebo
-
Stanford, CaliforniaStanford University
Sep 1, 2023
Autoantibodies, Interleukin-6 Trial in Frederiksberg (Oral Glucose Tolerance Test, Cycling test)
Recruiting
- Autoantibodies
- Interleukin-6
- Oral Glucose Tolerance Test
- Cycling test
-
Frederiksberg, DenmarkFrederiksberg Hospital
May 10, 2023
Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)
Not yet recruiting
- Sarcoidosis
- Abrocitinib 200 mg
-
New Haven, ConnecticutYale University
Jan 24, 2023
Seborrheic Dermatitis, Papulopustular Rosacea Trial in New York (PF-07038124, Placebo Ointment)
Recruiting
- Seborrheic Dermatitis
- Papulopustular Rosacea
- PF-07038124
- Placebo Ointment
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Aug 22, 2023
Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)
Active, not recruiting
- Melanoma
- MCS110
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 14, 2022
Type 1 Diabetes, Type 2 Diabetes Trial in Stockholm (N?-hydroxy-nor-arginine)
Recruiting
- Type 1 Diabetes
- Type 2 Diabetes
- Nω-hydroxy-nor-arginine
-
Stockholm, SwedenKarolinska Institutet
Apr 10, 2023